Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. (CKPT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ckpt · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Checkpoint Therapeutics, Inc. (CKPT) measures how much investors pay for each dollar of the company's trailing earnings. CKPT's current PE ratio of N/A is calculated by dividing its stock price of $4.26 by its TTM earnings per share of -$67.05.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2015 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Checkpoint Therapeutics, Inc.You CKPT | $368M | N/A | — | -$67.05 |
 Climb Bio, Inc. CLYM | $734M | N/A | — | -$0.88 |
 G1 Therapeutics, Inc. GTHX | $378M | N/A | — | -$0.93 |
 Inozyme Pharma, Inc. INZY | $258M | N/A | — | -$1.62 |
 iTeos Therapeutics, Inc. ITOS | $449M | N/A | — | -$3.32 |
 Orchard Therapeutics plc ORTX | $380M | N/A | — | -$0.62 |
 Revance Therapeutics, Inc. RVNC | $381M | N/A | — | -$3.83 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-1.42 | — | |
2023-12-31 FY2023 | — | $-2.77 | — | |
2022-12-31 FY2022 | — | $-7.09 | — | |
2021-12-31 FY2021 | — | $-7.45 | — | |
2020-12-31 FY2020 | — | $-4.13 | — | |
2019-12-31 FY2019 | — | $-7.00 | — | |
2018-12-31 FY2018 | — | $-12.74 | — | |
2017-12-31 FY2017 | — | $-10.03 | — | |
2016-12-31 FY2016 | — | $-10.43 | — | |
2015-12-31 FY2015 | — | $-5.69 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Checkpoint Therapeutics, Inc. (CKPT) measures how much investors pay for each dollar of the company's trailing earnings. CKPT's current PE ratio of N/A is calculated by dividing its stock price of $4.26 by its TTM earnings per share of -$67.05.
Frequently asked questions
CKPT pe ratio · 6 questionsCKPT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.26 and TTM EPS of -$67.05. Data sourced from Financial Modeling Prep via CKPT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Checkpoint Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09